| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
ARN22089 targets CDC42 (cell division control protein 42 homolog), a small GTPase of the Rho family that regulates cell migration, proliferation, and angiogenesis. As a CDC42 GTPase interaction inhibitor, it blocks the interaction of CDC42 with specific downstream effectors. The compound is classified under the Ras target and GPCR/G Protein and MAPK/ERK Pathway. By inhibiting CDC42 signaling, ARN22089 exerts its anticancer effects.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that ARN22089 is an orally active CDC42 GTPase interaction inhibitor that blocks the interaction of CDC42 with specific downstream effectors. It exhibits antiproliferative activity against human A-375 cells harboring the BRAF V600E mutant with an IC50 of 4.9 μM. ARN22089 specifically inhibits tumor angiogenesis in 3D vascularized microtumors. The compound shows drug-like properties in preclinical evaluations.
|
| ln Vivo |
In vivo activity of ARN22089 has been demonstrated in BRAF mutant mouse melanoma models where it blocks tumor growth. The compound also shows efficacy in patient-derived xenografts (PDXs). As an orally active compound, it is suitable for convenient administration in research settings. The compound's ability to inhibit tumor angiogenesis contributes to its antitumor efficacy in vivo. Detailed in vivo efficacy data, including dose-response relationships, are described in the literature.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for ARN22089 involves measuring its ability to inhibit the interaction of CDC42 GTPases with specific downstream effectors. The assay typically uses purified recombinant proteins or cell lysates to assess the disruption of CDC42-effector interactions. Antiproliferative activity is evaluated using CellTiter-Glo assays in human A-375 cells harboring the BRAF V600E mutant, with an IC50 of 4.9 μM. Standard protocols include appropriate positive controls and vehicle controls to ensure assay validity.
|
| Cell Assay |
In vitro cell-based assays for ARN22089 are conducted using human A-375 melanoma cells harboring the BRAF V600E mutant. Cells are treated with the compound at various concentrations, and cell viability is measured using CellTiter-Glo assays. The IC50 value for antiproliferative activity is 4.9 μM. The compound's effect on angiogenesis can be evaluated using 3D vascularized microtumor models. Standard protocols include appropriate positive controls such as known CDC42 inhibitors and vehicle controls.
|
| Animal Protocol |
In vivo animal studies for ARN22089 are conducted using BRAF mutant mouse melanoma models and patient-derived xenografts (PDXs). Animals are administered the compound orally at various doses, and tumor growth inhibition is monitored. The compound blocks tumor growth in these models. Pharmacokinetic parameters are determined from plasma samples. Tolerability is assessed by monitoring body weight changes and clinical signs. The compound's efficacy in inhibiting tumor angiogenesis is also evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ARN22089 include a molecular weight of 373.49 g/mol and a molecular formula of C23H27N5. Solubility includes DMSO at 100 mg/mL (267.74 mM) with ultrasonic and warming to 60°C. Storage recommendations include powder at -20°C for 3 years, 4°C for 2 years, and in solvent at -80°C for 6 months or -20°C for 1 month. The compound appears as a solid. Detailed pharmacokinetic parameters such as half-life and bioavailability are not extensively documented.
|
| Toxicity/Toxicokinetics |
Toxicity information for ARN22089 is limited in the available literature. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. It is a controlled substance and not for sale in certain territories. No detailed acute or chronic toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
ARN22089 is an orally active trisubstituted pyrimidine that blocks the interaction of CDC42 GTPases with specific downstream effectors. It blocks tumor growth in BRAF mutant mouse melanoma models and PDXs. It specifically inhibits tumor angiogenesis in 3D vascularized microtumors. It has a molecular weight of 373.49 g/mol and formula C23H27N5. It has an IC50 of 4.9 μM against A-375 cells. It is intended for research use only.
|
| Molecular Formula |
C23H27N5
|
|---|---|
| Molecular Weight |
373.493984460831
|
| Exact Mass |
373.226
|
| CAS # |
2248691-29-2
|
| PubChem CID |
142466546
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
458
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)C1=CC=CC(=C1)NC2=NC(=NC(=C2)C3=CC=CC=C3)C4CCNCC4
|
| InChi Key |
BWJICNGLWINASO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H27N5/c1-28(2)20-10-6-9-19(15-20)25-22-16-21(17-7-4-3-5-8-17)26-23(27-22)18-11-13-24-14-12-18/h3-10,15-16,18,24H,11-14H2,1-2H3,(H,25,26,27)
|
| Chemical Name |
3-N,3-N-dimethyl-1-N-(6-phenyl-2-piperidin-4-ylpyrimidin-4-yl)benzene-1,3-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~267.74 mM; with sonication (<60°C))
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6774 mL | 13.3872 mL | 26.7745 mL | |
| 5 mM | 0.5355 mL | 2.6774 mL | 5.3549 mL | |
| 10 mM | 0.2677 mL | 1.3387 mL | 2.6774 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
